Medicinal Chemistry Research Program (Project-003)

药物化学研究计划（Project-003）

• 批准号: 9369068
• 负责人: DEBORAH W KNAPP
• 金额: $ 2.84万
• 依托单位: PURDUE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9369068
• 关键词: Antineoplastic Agents; Award; Basic Science; Cancer Center Support Grant; Canis familiaris; Cells; Chemicals; Clinic; Collaborations; Development; Discipline; Drug Delivery Systems; Evaluation; Extramural Activities; Faculty; Faculty Recruitment; Funding; Grant; Human; In Vitro; Malignant Neoplasms; Malignant neoplasm of urinary bladder; Methods; Modeling; Molecular; NCI Center for Cancer Research; Paper; Peer Review; Pharmaceutical Chemistry; Phase; Phase III Clinical Trials; Program Research Project Grants; Publications; Recruitment Activity; Research; Research Personnel; Signal Transduction; Structure; Technology; Therapeutic Agents; Translations; Universities; anti-cancer therapeutic; base; college; comparative; drug discovery; faculty mentor; in vivo; in vivo Model; inter-institutional; meetings; member; novel; oncology; preclinical development; programs; protein protein interaction; screening; structural biology; therapeutic development; tool

Medicinal Chemistry Research Program: Project Summary The Medicinal Chemistry Program (MC) in the Purdue University Center for Cancer Research (PCCR) drives the drug discovery effort of the Center by serving as the central component for basic research in cancer drug discovery and drug discovery methods. The Program consists of 23 members who integrate their expertise in novel synthetic strategies and advanced technologies with the other Research Programs in the Center, to advance translation of promising entities to the clinic. During the past four years, nine new cancer- focused faculty members were recruited to the MC Program. MC members are united by a focus on cancer drug discovery, and represent diverse disciplines that are drawn from seven academic departments and four colleges from across the Purdue campus. The MC Program has a strong publication record, producing 286 papers between 2010 and 2013 with 2% involving intra-programmatic collaborations, 19% representing inter- programmatic and 21% engaging inter-institutional partners; overall, 39% MC publications were a result of collaborative efforts with other cancer researchers. Combined, the MC membership has a current portfolio of over $1.7 million of total direct peer-reviewed, extramural support, with 44% of awards being cancer-focused grants funded by the NCI, NSF, ACS or DOD. The MC Program is structured around two Research Clusters. Research Cluster 1, Synthetic Medicinal Chemistry, and the cornerstone of the MC Program, reflects the strengths of the Center in medicinal chemistry. A distinguished group of senior and junior faculty develops and utilizes target-based medicinal chemistry approaches to drug discovery. The efforts of this group have led to the development of 13 agents that have been in Phase 0, Phase I, Phase II, or Phase III clinical trials in the last funding cycle. Ten other agents have progressed to preclinical development (in vivo studies). Research Cluster 2, Target Discovery and Translation, encompasses a focus on target discovery, in vitro and in cell molecular evaluation of potential anti-cancer therapeutic agents, and the development and use of in vivo models and methods for the analysis of potential anti-cancer drugs. Tools have been developed for high- throughput single cell screening as well as in cell sensing and identifying protein-protein interaction networks. There is a specific emphasis on comparative oncology including studies of dogs with naturally-occurring cancers that closely mimic the human condition. The canine models are being evaluated for their impact on the translation of therapeutic agents to humans. Over the past four years, many MC projects have spawned highly productive inter-programmatic collaborations involving members of the Cell Identity and Signaling (CIS), Chemical and Structural Biology (CSB), and Drug Delivery and Molecular Sensing (DDMS) Programs. The Program Leader and Co-Leader's efforts in cancer-focused faculty recruiting and mentoring, and organizing Program meetings and the PCCR-based Bladder Cancer Discovery Group, have enhanced the two Research Clusters and overall research progress of the MC Program.

药物化学研究计划： 项目摘要 普渡大学癌症研究中心的药物化学计划(MC) 作为癌症基础研究的中心组成部分，推动该中心的药物发现工作 药物发现和药物发现方法。该计划由23名成员组成，他们将他们的 在新的合成策略和先进技术方面的专长，以及与其他研究计划的合作 中心，以促进有前途的实体到临床的翻译。在过去的四年里，九种新的癌症- 专注的教职员工被招募到MC项目中。MC成员因关注癌症而团结在一起 药物发现，代表了来自七个学术部门和四个学科的不同学科 普渡大学校园对面的大学。MC节目的出版记录很好，制作了286部 2010至2013年间的论文，其中2%涉及计划内协作，19%涉及计划间合作 方案和21%的机构间合作伙伴参与；总体而言，39%的MC出版物是 与其他癌症研究人员的合作努力。总而言之，MC成员目前的投资组合为 超过170万美元的直接同行审查和外部支持，其中44%的奖项是针对癌症的 由NCI、NSF、ACS或国防部资助的赠款。MC计划是围绕两个研究集群构建的。 研究分组1，合成药物化学，是MC计划的基石，反映了 该中心在药物化学方面的优势。一批杰出的高级和初级教职员工开发和 利用基于靶点的药物化学方法进行药物发现。这个小组的努力导致了 已处于0期、I期、II期或III期临床试验的13种药物的开发 上一个资金周期。其他十种药物已经发展到临床前开发(体内研究)。研究 第2组，靶标发现和翻译，重点放在体外和细胞内的靶标发现 潜在抗癌治疗药物的分子评价及体内应用研究进展 潜在抗癌药物分析的模型和方法。已开发出适用于高性能的工具 吞吐量单细胞筛选以及在细胞传感和识别蛋白质-蛋白质相互作用网络中。 特别强调比较肿瘤学，包括对自然发生的犬类的研究 与人类情况非常相似的癌症。犬类模型正在接受评估，以确定它们对 将治疗剂翻译到人类身上。在过去的四年里，许多MC项目催生了大量的 涉及小区标识和信令(CIS)成员的富有成效的方案间协作， 化学和结构生物学(CSB)以及药物输送和分子传感(DDMS)计划。这个 项目负责人和联合负责人在专注于癌症的教师招聘和指导以及组织方面的努力 项目会议和基于PCCR的膀胱癌发现小组加强了这两项研究 MC计划的集群和总体研究进展。